Jiangxi Qingfeng Pharmaceutical
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 12/1/2024
Pipeline by Phase
Therapeutic Focus
Clinical Trials (11)
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Started: 12/1/2024
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Started: 11/11/2024
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
Started: 7/28/2022
A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
Started: 1/8/2021
Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension
Started: 9/27/2024
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects
Started: 9/27/2024
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
Started: 4/26/2023
A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers
Started: 2/15/2023
A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers
Started: 10/26/2021
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
Started: 8/27/2020
Study of Aolanti Weikang Tablets in Healthy Volunteers
Started: 12/14/2017